Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Cerilliant
Dow
Medtronic
US Department of Justice
Harvard Business School
Chinese Patent Office
Queensland Health

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,746,429

« Back to Dashboard

Which drugs does patent 6,746,429 protect, and when does it expire?

Patent 6,746,429 protects OTREXUP and is included in one NDA.

This patent has thirteen patent family members in eight countries.
Summary for Patent: 6,746,429
Title: Needle assisted jet injector
Abstract:A needle assisted jet injector and method for jet injecting medicament are disclosed. In one embodiment of the injector, the needle is retractably located within an injector nozzle assembly. Upon activation of the force generating source, a portion of the needle extends past the nozzle assembly and penetrates the outer layer of skin to deliver the medicament via jet injection to a deeper region. After activation, the needle retracts back into the nozzle assembly. In another embodiment, the needle is fixed to the end of the nozzle assembly. In both embodiments, the length of the portion of the needle that penetrates the skin is less than 5 mm.
Inventor(s): Sadowski; Peter L. (Woodbury, MN), DeBoer; David M. (Brighton, MI), Berman; Claude L. (Ypsilanti, MI), Lesch, Jr.; Paul R. (Lexington, MN), Holland; Margaret L. (Rochester, NY)
Assignee: Antares Pharma, Inc. (Minneapolis, MN)
Application Number:09/779,603
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,746,429
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 6,746,429

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,746,429

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,776,015 Needle assisted jet injector ➤ Sign Up
RE44847 Needle assisted jet injector ➤ Sign Up
6,428,528 Needle assisted jet injector ➤ Sign Up
RE44846 Needle assisted jet injector ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
US Army
Fuji
Baxter
Express Scripts
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.